Stockscreener 앱 받기
29.71
0.74%
0.255
Moderna Inc 주식(MRNA)의 최신 뉴스
Moderna (MRNA) Sees Mild Bearish Sentiment Among Option Traders - GuruFocus
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE (COVID-19 Vaccine, mRNA) - Morris County NJ News | Daily Record
Insider Selling: Moderna (NASDAQ:MRNA) Director Sells 23,853 Shares of Stock - MarketBeat
Noubar Afeyan, Moderna director, sells $703k in MRNA stock - Investing.com
Moderna’s new COVID vaccine receives positive CHMP opinion By Investing.com - Investing.com India
Moderna (MRNA) Gains European Approval Nod for New COVID Vaccine - GuruFocus
Moderna’s new COVID vaccine receives positive CHMP opinion - Investing.com
Moderna (NASDAQ: MRNA) COVID shot mNEXSPIKE backed by EMA panel for EU nod - Stock Titan
Big COVID-19 Vaccine Update: Pfizer, Moderna Nearing Finish Line - cbn.com
Moderna on track to extend gains for the seventh straight trading day - MSN
Moderna to Host Investor Event – Analyst Day - York Dispatch
Bellevue Group AG Has $34.18 Million Stock Position in Moderna, Inc. $MRNA - MarketBeat
Banque Transatlantique SA Cuts Position in Moderna, Inc. $MRNA - MarketBeat
PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts - TipRanks
Moderna (NASDAQ:MRNA) Director Sells $13,910.40 in Stock - MarketBeat
Moderna 2026 Covid and RSV growth not enough to boost stock, Jefferies says - Proactive financial news
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Morningstar
ImmunityBio, Moderna among winners of EU drug recommendations this week - Seeking Alpha
EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike - TradingView
Moderna (MRNA) Faces Rising Short Interest Amid Sector Challenges - GuruFocus
Morgan Stanley Adjusts Moderna Price Target to $28 From $30, Maintains Equalweight Rating - marketscreener.com
MRNA: Jefferies Initiates Coverage with Hold Rating and $30 PT | - GuruFocus
Jefferies Initiates Coverage on Moderna With Hold Rating, $30 Price Target - marketscreener.com
Emergers: Equity Research | NANEXA: First license with Moderna an important validation of PharmaShell - TradingView — Track All Markets
Jefferies initiates Moderna stock with Hold rating, $30 price target - Investing.com
Moderna Stock On Fire: Up 23% With 7-Day Winning Streak - Trefis
Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze? - Stocktwits
Petition claims FDA oops! means COVID-19 vaccines misbranded - BioWorld MedTech
Moderna protects you from illness and poor vaccine information - WSBT
Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.? - GuruFocus
Moderna (MRNA) Q1 2025 Earnings Call Transcript - The Globe and Mail
Covid Shots Slash ER Visits for Kids in CDC Study - Bloomberg.com
Is the Market Bullish or Bearish on Moderna Inc? - Benzinga
Moderna signs deal worth up to $503m with Nanexa - Pharmaceutical Technology
Moderna and Super Micro top S&P 500 short interest list — are they ripe for a squeeze? - MSN
Moderna Secures $1.5B Five-Year Loan from Ares Management Ahead of Strategy Update - Finviz
US in "big danger" of falling behind in vaccine tech amid funding cuts, skepticism: Moderna co-founder - Seeking Alpha
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - GlobeNewswire Inc.
Moderna Founder Warns US Doubts on Science Threaten Biotech Edge - Bloomberg.com
Moderna Stock Rockets 21% With 6-Day Winning Streak - Trefis
Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products - TradingView — Track All Markets
Researchers Identify Immune Trigger Behind Myocarditis After Covid Vaccination - Bloomberg.com
Moderna Announces First Made-in-Canada mRNA Vaccines Delivered to Canadian Provinces and Territories - The Ames Tribune
Moderna Announces Updated COVID-19 Vaccine Against LP.8.1 Variant Generates Strong Immune Response in Humans - Livingston Daily
First Trust Advisors LP Has $34.02 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
FDA investigating possible adult deaths from COVID-19 vaccines - The Lewiston Tribune
Amundi Sells 425,861 Shares of Moderna, Inc. $MRNA - MarketBeat
Moderna (MRNA) Under Scrutiny as FDA Investigates Vaccine Safety - GuruFocus
FDA examines possible adult deaths from Covid-19 shots in probe - The Straits Times
FDA expands COVID-19 shot safety probe to include adultsreport - Seeking Alpha
FDA probes deaths likely related to COVID vaccines across age groups - Reuters
FDA Probes If Covid Shots Might Be Linked to Deaths of Adults - Bloomberg.com
Moderna, Pfizer, and BioNTech stock briefly dips on FDA Covid vaccine probe - Investing.com Canada
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy? - Finviz
Global AI Infrastructure Shift Ignites Biotech Growth Phase - Investing News Network
Dir Hussain Files To Sell 504 Of Moderna Inc [MRNA] - TradingView
Ossiam Has $3.08 Million Stake in Moderna, Inc. $MRNA - MarketBeat
CFO Mock Acquires 24,373 Of Moderna Inc [MRNA] - TradingView
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Fut - GuruFocus
Moderna (MRNA) Recently Broke Out Above the 50-Day Moving Average - Yahoo Finance
Invesco Ltd. Has $195.92 Million Holdings in Moderna, Inc. $MRNA - MarketBeat
Lido Advisors LLC Sells 140,814 Shares of Moderna, Inc. $MRNA - MarketBeat
0.56%
1.23%
자본화:
|
볼륨(24시간):